Sunday 18 October 2026
Export NVAX’s income statement to Excel — free account
Novavax, Inc.
NVAX Healthcare Biotechnology
Novavax, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 64.7% from fiscal 2024. In the quarter to June 2026, revenue fell 76.3%, EPS fell 148.5%, free cash flow grew 43.0% and total debt rose 31.5%, each against the same quarter a year earlier.
11.26
1.56
−12.17%
Follow NVAX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 2.45 | 4.09 |
+8 more quarters Free account |
P/S ratio |
3.75 | 2.23 | 0.97 | 1.32 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(21.29) | (40.99) | (27.58) | 13.06 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.72 | 1.39 | 0.52 | 0.83 | |
EV/EBITDA |
0.00 | 0.00 | 1.23 | 2.57 | |
EV/Operating CF |
(30.46) | (9.08) | (2.41) | (2.33) | |
EV/FCF |
(25.52) | (8.43) | (2.34) | (4.56) | |
Quick Ratio |
2.23 | 2.38 | 1.85 | 1.88 | |
Current Ratio |
2.33 | 2.48 | 2.13 | 2.27 | |
Net Debt/EBITDA |
8.22 | 40.22 | (25.82) | 3.08 | |
Debt/Assets |
30.68% | 28.08% | 20.94% | 20.86% | |
Debt/Equity |
(1.54) | (2.02) | (1.93) | (1.57) | |
Asset Turnover |
0.36 | 0.51 | 0.82 | 0.74 | |
Operating CF/Net income |
1.36 | 3.42 | (2.25) | (0.53) | |
Capex/Depreciation |
(0.19) | (0.41) | (0.44) | (0.31) | |
Interest Coverage |
(9.65) | (3.15) | 2.44 | (32.47) | |
Research and Development Expense of Revenue |
124.68% | 68.43% | 51.57% | 139.50% | |
Selling, General and Administrative Expense of Revenue |
47.03% | 20.63% | 23.19% | 44.94% | |
Intangible Assets out of Total Assets |
0.12 | 0.11 | 0.10 | 0.10 | |
Share Based Compensation of Revenue |
14.27% | 5.54% | 5.41% | 12.14% | |
Graham Net Nets |
(0.24) | (0.25) | (0.30) | (0.26) | |
Graham Number |
6.30 | 3.28 | 0.00 | 0.00 | |
Earnings Yield |
(16.14%) | (6.63%) | 40.77% | 24.45% | |
Free Cash Flow Yield |
(2.84%) | (7.42%) | (23.15%) | (13.72%) | |
Revenue per Share |
0.34 | 0.85 | 0.91 | 0.43 | |
Operating CF per Share |
(0.44) | (0.20) | (0.24) | 0.66 | |
Capex per Share |
0.00 | (0.01) | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.45) | (0.21) | (0.26) | 0.65 | |
Cash per Share |
4.37 | 4.84 | 4.60 | 4.77 | |
Shareholders Equity per Share |
(1.16) | (0.89) | (0.79) | (0.96) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.16) | (0.89) | (0.79) | (0.96) | |
Free Cash Flow |
(73.39) | (33.69) | (41.72) | 105.79 | |
Working Capital |
440.52 | 508.36 | 518.33 | 544.72 | |
Capital Expenditures |
(0.59) | (1.27) | (2.25) | (2.02) | |
Net Current Asset Value |
(375.18) | (337.11) | (325.99) | (361.97) | |
EV/EBIT |
0.00 | 0.00 | 1.30 | 2.86 | |
Capex to Sales |
0.01 | 0.01 | 0.02 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 2.40 | 4.58 | |
| Other line items | |||||
Average Receivables |
122.57 | 33.91 | 107.37 | 64.57 | |
Average Payables |
36.77 | 25.13 | 33.08 | 36.37 | |
Average Inventory |
10.12 | 10.86 | 10.15 | 11.07 | |
Average Assets |
1,146.06 | 1,168.08 | 1,368.47 | 1,446.19 | |
Average Common Equity |
(76.54) | (110.20) | (375.80) | (341.55) |
Columns are period end dates